Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors

Molecular Cancer Research

Volumn 12, Issue 5, 2014, Pages 694-702

  Panosyan, Eduard H ^a   Wang, Yuntao ^a   Xia, Peng ^a   Lee, Wai Nang Paul ^a   Pak, Youngju ^a   Laks, Dan R ^b   Lin, Henry J ^a   Moore, Theodore B ^b,c   Cloughesy, Timothy F ^c   Kornblum, Harley I ^b,c   Lasky III, Joseph L ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTATE AMMONIA LIGASE; ETOPOSIDE; GEMCITABINE; GLUTAMINE; MESSENGER RNA; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; ASPARAGINASE; DACARBAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME SYNTHESIS; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MEDULLOBLASTOMA CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DEFICIENCY; DNA DAMAGE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; GLIOBLASTOMA; MALE; MEDULLOBLASTOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ASPARAGINE; ASPARTATE-AMMONIA LIGASE; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DACARBAZINE; DNA DAMAGE; DRUG SYNERGISM; GLIOBLASTOMA; GLUTAMINE; HUMANS; MALE; MEDULLOBLASTOMA; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900384684     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0576     Document Type: Article

References (44)

1. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl JMed 1948;238:787-93.
2. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84.
3. Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H. Effective dose of l-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from childrens cancer study group. Cancer Res 1979;39:3893-6.
4. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokineti 2005;44:367-93.
5. Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 2004;24:5.
6. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 2004;18:107-12.
7. Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int J Cancer 2010;127:2478-85.
8. Najim N, Podmore ID, Mcgown A, Estlin EJ. Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. Anticancer Res 2009;29:3103-8.
9. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, et al. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 2001;61: 4017-23.
10. Albrecht J, Sidoryk-Wȩgrzynowicz M, Zielin'ska M, Aschner M. Roles of glutamine in neurotransmission. Neuron Glia Biol 2010;6:263-76.
11. Taylor SA, Crowley J, Pollock TW, Eyre HJ, Jaeckle C, Hynes HE, et al. Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. J Clin Oncol 1991;9:1476-9.
12. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol 1999;17:984.
13. Dranoff G, Elion GB, Friedman HS, Bigner DD. Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma. Cancer Res 1985;45:4082-6.
14. Dranoff G, Elion GB, Friedman HS, Campbell GL, Bigner DD. Influence of glutamine on the growth of human glioma and medulloblastoma in culture. Cancer Res 1985;45:4077-81.
15. Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335-41.
16. Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Würthwein G, Janka-Schaub G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m2 PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006;46: 18-25.
17. Panetta JC, Gajjar A, Hijiya N, Hak LJ, Cheng C, Liu W, et al.. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;86:651-8.
18. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J 2001;357:321-8.
19. Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, et al. Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 2008;7: 3123-8.
20. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, et al. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 2012;180: 895-903.
21. Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, et al. Enhanced expression of asparagine synthetase under glucosedeprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res 2007;67: 3345-55.
22. Von Bueren AO, Bacolod MD, Hagel C, Heinimann K, Fedier A, Kordes U, et al. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. Br J Cancer 2012;107:1399-408.
23. Friedman HS, Colvin OM, Kaufmann SH, Ludeman SM, Bullock N, Bigner DD, et al. Cyclophosphamide resistance in medulloblastoma. Cancer Res 1992;52:5373-8.
24. Jacobsen PF, Jenkyn DJ, Papadimitriou JM. Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neurol 1985;44:472-85.
25. Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, et al. Differential effects of the proteasome inhibitor NPI-0052 against glioma cells. Transl Oncol 2010;3:50-5.
26. Stafford P, Abdelwahab MG, Kim do Y, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 2010;7:74.
27. Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, et al. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multipassageable neurosphere formation. Pediatr Blood Cancer 2010;55:644-51.
28. Levy JM, Thorburn A. Modulation of pediatric brain tumor autophagy and chemosensitivity. J Neurooncol 2012;106:281-90.
29. Irino T, Kitoh T, Koami K, Kashima T, Mukai K, Takeuchi E, et al. Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression. J Mol Diagnostics 2004;6:217-24.
30. Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther 2011;10:1818-28.
31. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009;27:980-7.
32. Cooper C, Packer N, Williams K. Amino acid analysis protocols. Methods in Molecular Biology, Totawa, NJ: Humana Press; 2000.
33. Reynolds CP, Sun BC, DeClerck YA, Moats RA. Assessing growth and response to therapy in murine tumor models. Methods Mol Med 2005;111:335-50. 2005.
34. Slinker BK. The statistics of synergism. J Mol Cell Cardiol 1998; 30:723-31.
35. Covini DTS, Bussolati O, Chiarelli LR, Pasquetto MV, Digilio R, Valentini G, et al. Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat Anticancer Drug Discov 2012;7:4-13.
36. Piek J, Adelt T, Huse K, Bock WJ. Cerebrospinal fluid and plasma aminograms in patients with primary and secondary tumors of the CNS. Infusionsther Klin Ernahr 1987;14:73-7.
37. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 2013;19:901-8.
38. Szeliga M, Zgrzywa A, Obara-Michlewska M, Albrecht J. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. J Neurochem 2012;123:428-36.
39. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 2011;108:16062-7.
40. Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR. Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg 2013;119:427-33.
41. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18:500-9.
42. Langen K-J, Tatsch K, Grosu A-L, Jacobs AH, Weckesser M, Sabri O. Diagnostics of cerebral gliomas with radiolabeled amino acids. Dtsch Arztebl Int 2008;105:55-61.
43. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010;28:2220-6.
44. Richards NGJ, Kilberg MS. Asparagine synthetase chemotherapy. Annu Rev Biochem 2006;75:629-54.